Lambert-Eaton Myasthenic Syndrome Market By Treatment (Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2019 to 2027.  LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).

"Recent FDA approval of amifampridine for treating LEMS in children and fast track & orphan drug designation to incentivize its growth during the forecast period"

Currently there is no permanent cure for the treatment of LEMS disease in children, the medicine prescribed by physicians worldwide are to attenuate the clinical manifestations related to LEMS disease. Depending on the identification of the symptoms occurring in the adult population the drugs prescribed for its treatment are potassium channel blockers, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin, Plasmapheresis etc. USFDA has recently approved amifampridine for the treatment of LEMS in children from 6 to 17 years of age. It has received orphan drug and fast track designation status which will proactively incentivize the drug development for curing rare diseases.

"Significant rise in clinical research to cure orphan diseases and domicile of major players together drive the market growth in North America region"

North America is currently dominating the regional segment for Lambert-Eaton Myasthenic syndrome (LEMS) market holding 39% share. The major factors responsible for its positive growth profile are significant rise in clinical research activities to cure orphan diseases. According to the Center for Disease Control and Prevention (CDC), research findings approximately 3% of the patients suffering with small cell lung cancer (SCLC) are suffering with Lambert-Eaton Myasthenic syndrome (LEMS). The prevalence rate of SCLC in the United States is 5 cases per million population. Domicile of major players such as Biomarin Pharmaceutical, Inc., Catalyst, Pharmaceuticals, Inc., 

Merck & Co., Inc. etc. propel the market growth in North America region. Europe holds the second position representing a market share of 34.5% owing to the high incidence rate of LEMS in the European community. As per the research citing of European LEMS Registry the incidence rate is 0.48 to 0.75 per million people, the low prevalence rate I comparison to the incidence rate is due to the poor survival of LEMS patient with paraneoplastic type of disease. Asia Pacific is currently holding 14% market share primarily due to large patient population suffering with SCLC and proactive government initiatives in providing financial aid for the treatment of rare diseases.

Historical & Forecast Period

This research report presents the analysis of each segment from 2017 to 2027 considering 2018 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by treatment and by geography. 

Pharmaceutical manufacturers providing medications for the treatment of Lambert-Eaton Myasthenic Syndrome are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation.

Key questions answered in this report

• Which pharmaceutical companies are engaged in the treatment of LEMS?
• What is the global prevalence rate of LEMS and clinical manifestation overlapping with cancer?
• Brief explanation of DRO’s associated with LEMS market?
• Which drug received the USFDA orphan drug and fast track designation for the treatment of LEMS in children?
• What is the incidence rate in developed countries such as Europe and North America?